Evolving patterns in a collaboration network of global R&D on monoclonal antibodies
Evolving patterns in a collaboration network of global R&D on monoclonal antibodies
复制标题
全球 R 协作网络中不断演变的模式
DOI：
10.1080/19420862.2017.1356527
复制
发表时间：
2017
期刊：
影响因子：
5.3
通讯作者：
Yuanjia Hu
中科院分区：
文献类型：
--
作者：
Xiangjun Kong;J. Wan;Hao Hu;S. Su;Yuanjia Hu
摘要我们研究了过去30年来单抗研发(R&D)的组织间协作网络的演变过程。每年对协作网络的检测提供了不同组织之间网络结构和关系变化的动态变化。我们的研究表明，由于新组织的不断进入和新合作伙伴关系的建立，网络的规模和复杂性不断增长。不断演变的拓扑特征揭示了随着时间的推移变得更加清晰的核心-外围结构，以及协作单抗研发网络中日益增长的异质性。以网络参与者的数量衡量，专门的生物技术公司是单抗开发领域的主导组织形式，但在2004-2009年期间，当制药公司接管专职生物技术公司的职位时，它们的平均中心地位有所下降。随着网络的演变，技术创新和并购(M&A)推动了两次领先地位的替代浪潮。此外，本研究分析了组织层面的行为，以帮助理解不同技术创新或经济背景下单抗开发领域网络结构的演变。
ABSTRACT We investigated the evolution process of collaborative inter-organizational network of the research and development (R&D) on monoclonal antibody (mAb) over the past 30 y. The annual detection of the collaboration network provides dynamics on network structures and relationship changes among different organizations. Our research showed continuous growth of the network's scale and complexity due to the constant entry of new organizations and the forging of new partnering relationships. The evolving topological features reveal a core-periphery structure that became clearer over time and an increasing heterogeneity within the collaborative mAb R&D network. As measured by the number of network participants, dedicated biotechnology firms (DBFs) were the dominant organization form in the field of mAb development, but their average centrality was reduced during the period of 2004–2009, when pharmaceutical companies took over the positions of DBFs. Along with the network evolution, 2 waves of substitution on the leading positions were driven by technological innovations and mergers and acquisitions (M&A). In addition, this study analyzed organizational-level behaviors to help understand the evolution of network structures over the field of mAb development across the different technologically innovative or economic contexts.